GIC,GBM

Mengxi Zhu1,2, Mengting Yang1,3, Rui Li1,2

  • 1Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, China.

Nature communications
|December 18, 2025
PubMed
概括

这项研究引入了一种新的可注射平台,用于对抗多形质母细胞瘤 (GBM) 复发. 该疗法向剩余的质瘤发起细胞 (GIC),并扭转了手术后的免疫抑制瘤微环境.